Concise review: Stem cell therapies for neuropathic pain

Stem Cells Translational Medicine

Volumn 2, Issue 5, 2013, Pages 394-399

  Fortino, Veronica R ^a   Pelaez, Daniel ^b   Cheung, Herman S ^a,b  

^a University of Miami College of Engineering   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adult stem cells; Cellular therapy; Neuropathy; Stem cell microenvironment interactions

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; PROSTAGLANDIN; PURINERGIC P2X4 RECEPTOR; SUBSTANCE P;

ALLODYNIA; BLOOD FLOW; CELL CONTACT; CELL POPULATION; CELL THERAPY; CENTRAL NERVOUS SYSTEM SENSITIZATION; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HYPERALGESIA; INFLAMMATION; MESENCHYMAL STEM CELL; NERVE INJURY; NERVE REGENERATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; RATING SCALE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TISSUE INJURY; VASODILATATION;

EID: 84877640951     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0122     Document Type: Review

References (25)

1. Treede R, Jensen T, Campbell J et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-1635.
2. Baron R. Mechanisms of disease: Neuropathic pain: A clinical perspective. Nat Clin Pract Neurol 2006;2:95-106.
3. Smith B, Torrance N, Bennett M et al. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-149.
4. Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9: 807-819.
5. Urgellés-Lorié L. Nociceptive vs. neuropathic pain: Physiological regulating medicine (PRM)/new approach for its control. Dolor, Clinica y Terapia 2008;17-22.
6. Moore K, Kohno T, Karchewski L et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002;22:6724-6731.
7. Coull J, Boudreau D, Bachand K et al. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 2003;424:938-942.
8. Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor from microglia: A molecular substrate for neuropathic pain. Neuron Glia Biol 2011;7:99-108.
9. Wu G, Ringkamp M, Hartke T et al. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001;21:RC140.
10. Ossipov M. Growth factors and neuropathic pain. Curr Pain Headache Rep 2011;15: 185-192.
11. Apfel S. Neurotrophic factors in peripheral neuropathies: Therapeutic implications. Brain Pathol 1999;9:393-413.
12. Cova L, Armentero M, Zennaro E et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Res 2010;1311:12-27.
13. Koh S, Kim K, Choi M et al. Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 2008;1229: 233-248.
14. Nesti C, Pardini C, Barachini S et al. Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone. Brain Res 2011;1367:94-102.
15. Reid A, Sun M, Wiberg M et al. Nerve repair with adipose-derived stem cells protects dorsal root ganglia neurons from apoptosis. Neuroscience 2011;199:515-522.
16. Park H, Lee P, Bang O et al. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 2008;107:141-151.
17. Edalatmanesh M, Bahrami A, Hosseini E et al. Neuroprotective effects of mesenchymal stem cell transplantation in animal model of cerebellar degeneration. Neurol Res 2011;33:913-920.
18. Sarnowska A, Braun H, Sauerzweig S et al. The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. Exp Neurol 2009;215:317-327.
19. Wilkins A, Kemp K, Ginty M et al. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009;3:63-70.
20. Wang F, Yasuhara T, Shingo T et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: Focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 2010;11:52.
21. Siniscalco D, Giordano C, Galderisi U et al. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice. Cell Mol Life Sci 2010;67:655-669.
22. Siniscalco D, Giordano C, Galderisi U et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci 2011;5:79.
23. Shibata T, Naruse K, Kamiya H et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008;57:3099-3107.
24. Kim B, Jin H, Bae J. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. Lab Anim Res 2011;27: 171-176.
25. Ichim T, Solano F, Lara F et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report. Int Arch Med 2010;3:30.